A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis
A legfontosabb adatok
- Ki végzi
- Hoffmann-La Roche
- Hol
- Aurora, Birmingham, Boston, Cleveland, Milwaukee, New York, Newport Beach, Rochester, San Francisco és Washington D.C. (Egyesült Államok)Mind a 11 helyszín megnézéseMég 16 másik országban, 56 helyszínen
- Állapot
- Fut, nem toboroz
- Fázis
- 3. fázis
- Résztvevők
- 122 fő vett részt
- Kezdés
- 2022. szept. 27.
- Várható befejezés
- 2028. dec. 14.
- A vizsgálat típusa
- Beavatkozással járó, 4 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
- A vizsgált kezelések
- Satralizumab
- Placebo
- A regiszteradat frissítve
- 2026. október 8.
Ki vehet részt
- Életkor
- 12 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 42 feltétel megnézéseKevesebb
Ki vehet részt
- Reasonable exclusion of tumor or malignancy before baseline visit (randomization)
- Onset of AIE symptoms ≤ 9 months before randomization
- Meet the definition of "New Onset" or "Incomplete Responder" AIE
- For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use adequate contraception during the treatment period and for at least 3 months after the final dose of satralizumab or placebo
- For participants enrolled in the extended China enrollment phase at China's sites: participants who are current residents of mainland China, Hong Kong, or Taiwan, and of Chinese ancestry; NMDAR AIE Cohort:
- Age ≥ 12 years
- Diagnosis of probable or definite NMDAR encephalitis; LGI1 AIE Cohort
- Age ≥ 18 years
- Diagnosis of LGI1 encephalitis
Ki nem vehet részt
- History of carcinoma or malignancy, unless deemed cured by adequate treatment with no evidence of recurrence for ≥ 5 years before screening
- Historically known positivity to any cell surface neuronal antibodies other than NMDAR and LGI1, in the absence of NMDAR and LGI1 antibody positivity
- History of herpes simplex virus encephalitis in the previous 24 weeks
- Any previous/concurrent treatment with interleukin-6 (IL-6) inhibitory therapy (e.g., tocilizumab), alemtuzumab, total body irradiation, or bone marrow transplantation
- Any previous treatment with T-cell depleting therapies, cladribine, or mitoxantrone
- Treatment with oral cyclophosphamide within 1 year prior to baseline
- Treatment with any investigational drug (including bortezomib) within 24 weeks prior to screening
- Concurrent use of more than one immunosuppressive therapy (IST) as background therapy
- Contraindication to all of the following rescue treatments: rituximab, intravenous immunoglobulin (IVIG), high-dose corticosteroids, or intravenous (IV) cyclophosphamide
- Any surgical procedure, except laparoscopic surgery or minor surgeries within 4 weeks prior to baseline, excluding surgery for thymoma or teratoma removal
- Planned surgical procedure during the study
- Evidence of serious uncontrolled concomitant diseases
- Infection requiring hospitalization or treatment with IV anti-infective agents within 4 weeks prior to baseline visit
- History of drug or alcohol abuse within 1 year prior to baseline
- History of diverticulitis or concurrent severe gastrointestinal (GI) disorders that, in the investigator's opinion, may lead to increased risk of complications such as GI perforation
- Receipt of live or live-attenuated vaccine within 6 weeks prior to baseline visit
- History of suicide attempt within 3 years prior to screening except if this is clearly associated with and occurs during the acute phase of LGI-1 or NMDAR encephalitis
- Pregnant or breastfeeding, or intending to become pregnant during the study or within 3 months after the final dose of study drug
- For participants with NMDAR AIE, history of negative anti-NMDAR antibody in cerebrospinal fluid (CSF) using a cell-based assay within 9 months of symptom onset
- Historically known positivity to an intracellular antigen with high cancer association or glutamate decarboxylase 65 (GAD-65)
- Confirmed central nervous system (CNS) or peripheral nervous system (PNS) demyelinating disease
- Congenital or acquired immunodeficiency, including human immunodeficiency virus (HIV) infection
- Active or presence of recurrent bacterial, viral, fungal, mycobacterial infection, or other infection
- Positive hepatitis B (HBV) and hepatitis C (HCV) test at screening
- Evidence of latent or active tuberculosis (TB)
- History of severe allergic reaction to a biologic agent
- Any previous treatment with anti-cluster of differentiation 19 antibody (CD19 antibody), complement inhibitors, neonatal Fc receptor antagonists, anti-B-lymphocyte stimulator monoclonal antibody
- History of blood donation (1 unit or more), plasma donation or platelet donation within 90 days prior to screening
- Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes safe participation in and completion of the study
- Any untreated teratoma or thymoma at baseline visit (randomization)
- Confirmed paraneoplastic encephalitis
- Alternative causes of associated symptoms
- Evidence of progressive multifocal leukoencephalopathy
Helyszínek itt: Egyesült Államok
Még 16 másik országban, 56 helyszínen
- University of ColoradoAurora, Egyesült Államok
- University of Alabama at BirminghamBirmingham, Egyesült Államok
- Brigham and Women's Hospital Department of NeurologyBoston, Egyesült Államok
- Cleveland Clinic FoundationCleveland, Egyesült Államok
- University Hospitals Of ClevelandCleveland, Egyesült Államok
- Medical College of WisconsinMilwaukee, Egyesült Államok
- NYU Langone Medical CenterNew York, Egyesült Államok
- Hoag Memorial HospitalNewport Beach, Egyesült Államok
- Mayo Clinic - RochesterRochester, Egyesült Államok
- UCSF- Multiple Sclerosis CentreSan Francisco, Egyesült Államok
- Childrens National Health CenterWashington D.C., Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
The purpose of this study is to assess the efficacy, safety, PK, and PD of satralizumab in participants with NMDAR and LGI1 encephalitis.
A vizsgálat 4 csoportja
- NMDAR Autoimmune Encephalitis (AIE) CohortA vizsgált kezelés
Adults and adolescents with definite or probable NMDAR encephalitis will receive satralizumab as per the schedule specified in the protocol. As of Protocol Version 6, participants in Part 1 will transition to Part 2 at the time of primary analysis or at Week 52, whichever occurs first.
Kezelés: Satralizumab
- LGI1 AIE CohortA vizsgált kezelés
Adults with LGI1 encephalitis as per the schedule specified in the protocol.
Kezelés: Satralizumab
- NMDAR AIE Placebo CohortPlacebo, összehasonlításként
Adults and adolescents with definite or probable NMDAR encephalitis will receive satralizumab placebo as per the schedule specified in the protocol. As of Protocol Version 6, participants in Part 1 will transition to Part 2 at the time of primary analysis or at Week 52, whichever occurs first.
Kezelés: Placebo
- LGI1 AIE Placebo CohortPlacebo, összehasonlításként
Adults with LGI1 encephalitis will receive satralizumab placebo as per the schedule specified in the protocol.
Kezelés: Placebo
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
- Hivatalos cím
- A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Basket Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis
- A regiszteradat frissítve
- 2026. október 8.